Similar articles

• Anti-tuberculosis 4FDC tablets--mystery to chemistry.

  Dekker TG, Lötter AP. Dekker TG, et al. Int J Tuberc Lung Dis. 2003 Mar;7(3):205-6. Int J Tuberc Lung Dis. 2003. PMID: 12661831 No abstract available.
• Tuberculosis control programme guidelines--treatment regimens.

  Durrheim DN, Belt EL. Durrheim DN, et al. S Afr Med J. 1996 Oct;86(10):1293-4. S Afr Med J. 1996. PMID: 8955740 No abstract available.
• Rapid oral tolerance induction to isoniazid and pyrazinamide and controlled administration of ethambutol: clinical case.

  Rodrigues Carvalho S, Silva I, Leiria-Pinto P, Rosado-Pinto J. Rodrigues Carvalho S, et al. Allergol Immunopathol (Madr). 2009 Nov-Dec;37(6):336-8. doi: 10.1016/j.aller.2009.05.006. Allergol Immunopathol (Madr). 2009. PMID: 19875222 No abstract available.
• New trends in the chemotherapy of tuberculosis--current aspects.

  Zierski M. Zierski M. Pneumonologie. 1974 Jun 14;150(1):1-12. doi: 10.1007/BF02097148. Pneumonologie. 1974. PMID: 4135222 Review. No abstract available.
• Present status of chemotherapy for tuberculosis.

  Grosset JH. Grosset JH. Rev Infect Dis. 1989 Mar-Apr;11 Suppl 2:S347-52. doi: 10.1093/clinids/11.supplement_2.s347. Rev Infect Dis. 1989. PMID: 2652251 Review.